Io Therapeutics, Inc., presented today results from studies of IRX4204
资讯
2024-07-17
Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its poten...